234 related articles for article (PubMed ID: 31650943)
1. [Clinical Diagnosis and Treatment Recommendations for the Pneumonitis Associated with Immune Checkpoint Inhibitor].
Wang H; Guo X; Zhou J; Duan L; Si X; Zhang L; Li Y; Liu X; Wang M; Shi J; Zhang L
Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):621-626. PubMed ID: 31650943
[TBL] [Abstract][Full Text] [Related]
2. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis.
Wang H; Guo X; Zhou J; Li Y; Duan L; Si X; Zhang L; Liu X; Wang M; Shi J; Zhang L
Thorac Cancer; 2020 Jan; 11(1):191-197. PubMed ID: 31762218
[TBL] [Abstract][Full Text] [Related]
3. [Clinical Diagnosis and Treatment Recommendations for Ocular Toxicities of Target Therapy and Immune Checkpoint Inhibitor Therapy].
Liu X; Wang Z; Zhao C; Wang H; Guo X; Zhou J; Duan L; Si X; Zhang L; Li Y; Wang M; Shi J; Zhang M; Zhang L
Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):653-660. PubMed ID: 31650949
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor-Related Pneumonitis.
Gomatou G; Tzilas V; Kotteas E; Syrigos K; Bouros D
Respiration; 2020; 99(11):932-942. PubMed ID: 33260191
[TBL] [Abstract][Full Text] [Related]
5. Recurrent delayed immune-related pneumonitis after immune-checkpoint inhibitor therapy for advanced osteosarcoma.
Küçükarda A; Gökmen İ; Özcan E; Peker P; Akgül F; Çiçin İ
Immunotherapy; 2022 Apr; 14(6):395-399. PubMed ID: 35152716
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.
Zhang Q; Tang L; Zhou Y; He W; Li W
Front Immunol; 2021; 12():663986. PubMed ID: 34122422
[TBL] [Abstract][Full Text] [Related]
7. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond.
Reuss JE; Suresh K; Naidoo J
Curr Oncol Rep; 2020 May; 22(6):56. PubMed ID: 32415399
[TBL] [Abstract][Full Text] [Related]
9. Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy.
Suresh K; Psoter KJ; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; Hales RK; D'Alessio F; Danoff SK; Naidoo J
J Thorac Oncol; 2019 Mar; 14(3):494-502. PubMed ID: 30503891
[TBL] [Abstract][Full Text] [Related]
10. Lessons from the diagnosis and treatment of severe immune checkpoint inhibitor-associated pneumonia: a case report.
Weng F; Wei J; Sang M; Gao X; Zhang P; Fu Q
Immunotherapy; 2023 Aug; 15(12):897-903. PubMed ID: 37337737
[TBL] [Abstract][Full Text] [Related]
11. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary Toxicities of Immunotherapy.
Altan M; Zhong L; Shannon VR; Sheshadri A
Adv Exp Med Biol; 2021; 1342():357-375. PubMed ID: 34972974
[TBL] [Abstract][Full Text] [Related]
13. Immune-Related Adverse Events: Pneumonitis.
Zhong L; Altan M; Shannon VR; Sheshadri A
Adv Exp Med Biol; 2020; 1244():255-269. PubMed ID: 32301020
[TBL] [Abstract][Full Text] [Related]
14. Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis.
Shu Y; Xu W; Su R; Ran P; Liu L; Zhang Z; Zhao J; Chao Z; Fu G
Front Immunol; 2023; 14():1251645. PubMed ID: 37799725
[TBL] [Abstract][Full Text] [Related]
15. [Clinical Diagnosis and Treatment Recommendations for Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor].
Guo X; Wang H; Zhou J; Duan L; Li Y; Si X; Zhang L; Fang L; Zhang L
Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):627-632. PubMed ID: 31650944
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.
Suresh K; Naidoo J; Lin CT; Danoff S
Chest; 2018 Dec; 154(6):1416-1423. PubMed ID: 30189190
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study.
Wang H; Zhao Y; Zhang X; Si X; Song P; Xiao Y; Yang X; Song L; Shi J; Zhao H; Zhang L
Cancer Med; 2021 Jan; 10(1):188-198. PubMed ID: 33211395
[TBL] [Abstract][Full Text] [Related]
18. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.
Suresh K; Naidoo J; Zhong Q; Xiong Y; Mammen J; de Flores MV; Cappelli L; Balaji A; Palmer T; Forde PM; Anagnostou V; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Lin CT; Feller-Kopman D; Lerner AD; Lee H; Shafiq M; Yarmus L; Lipson EJ; Soloski M; Brahmer JR; Danoff SK; D'Alessio F
J Clin Invest; 2019 Jul; 129(10):4305-4315. PubMed ID: 31310589
[TBL] [Abstract][Full Text] [Related]
19. Multiple rechallenges with anti-PD-1 immunotherapy in patients with checkpoint inhibitor-related pneumonitis: A report of two cases.
Yan Z; Yao S; Yuan J; Liu Y; Yao Z
J Oncol Pharm Pract; 2022 Jul; 28(5):1234-1238. PubMed ID: 35037786
[TBL] [Abstract][Full Text] [Related]
20. A Novel Workflow to Create a Checkpoint Inhibitor Pneumonitis Patient Registry.
Faucheux A; Olson E; Lantz J; Roberts N; Aggarwal V; Newman I; Ponnatapura J; Lycan T
Cureus; 2023 Feb; 15(2):e34683. PubMed ID: 36909081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]